Search
Loxoprofen
go.drugbank.com/drugs/DB09212ApprovedInvestigationalA transdermal preparation was approved for use in Japan in January 2006. … It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina.
Milnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalimportant role in the mitigation of pain signals in the descending inhibitory pain pathways in the brain and spinal cord [A175759, A175843, A175846]. … Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment
Nabumetone
go.drugbank.com/drugs/DB00461ApprovedNabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.[L6568] … [A179077] While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.
Mixtures: NuDroxiPAK N-500Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigationalPrimary biliary cirrhosis, or PBC, is a progressive and chronic condition that leads to hepatic injury often resulting in end-stage liver failure that requires liver transplantation. … The NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636]
Teduglutide
go.drugbank.com/drugs/DB08900ApprovedInvestigationalFDA approved on December 21, 2012.
Categories: Compounds used in a research, industrial, or household settingPenpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigational[A273848] In order to further reduce the risk of toxicities and improve efficacy, penpulimab was designed with Fc mutations in order to eliminate Fc receptor and complement-mediated effector function, … [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998]
Isatuximab
go.drugbank.com/drugs/DB14811ApprovedInvestigational[L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma. … Following three consecutive years on the yearly "Antibodies to watch" list published in "mAb", a peer-reviewed scientific journal dedicated to antibody research,[A38676,A191826,A191829] isatuximab was
Influenza A virus A/Christchurch/16/2010 NIB-74 (H1N1) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10781ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Physicians EZ Use Flu Kit, Medical Provider Single Use EZ Flu Shot KitHexobendine
go.drugbank.com/drugs/DB13265ApprovedIt has not been approved in the United States or the United Kingdom, but has been used widely in Austria and Germany [T478].
Categories: Vasodilators Used in Cardiac DiseasesNetupitant
go.drugbank.com/drugs/DB09048ApprovedInvestigationalNetupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy
Synonyms: 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide